UNCY
Unicycive Therapeutics IncKey Statistics
About Unicycive Therapeutics Inc
Unicycive Therapeutics Inc. is a clinical-stage biopharmaceutical company committed to transforming the landscape of kidney disease treatment, particularly in addressing hyperphosphatemia and its associated disorders. With its innovative pipeline aimed at regulating phosphorus levels through unique therapeutic mechanisms, Unicycive seeks to improve patient outcomes significantly. The company's strong focus on research and development, coupled with strategic collaborations, positions it well to lead advancements in nephrology care. As Unicycive progresses through its clinical trials, it presents a compelling investment opportunity for institutional investors looking to capitalize on growth in the evolving healthcare sector.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-29.48M |
| Operating Margin | 0.00% |
| Return on Equity | -141.10% |
| Return on Assets | -45.70% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $1.36 |
| Price-to-Book | 5.54 |
| Price-to-Sales (TTM) | 23.75 |
| EV/Revenue | 16.63 |
| EV/EBITDA | -1.03 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $25.24M |
| Float | $22.82M |
| % Insiders | 2.49% |
| % Institutions | 34.03% |
Historical Volatility
Volatility is currently expanding